Anlotinib Hydrochloride: Precision Multi-Target Tyrosine Kinase Inhibition for Cancer Research

Executive Summary: Anlotinib hydrochloride is a novel anti-angiogenic small molecule that selectively inhibits VEGFR2, PDGFRβ, and FGFR1 at nanomolar concentrations (source: Gene 2018). In vitro, it blocks VEGF/PDGF-BB/FGF-2-induced endothelial cell migration and capillary tube formation with superior potency to sunitinib, sorafenib, and nintedanib (source: Gene 2018). Pharmacokinetic profiling in rats and dogs confirms good oral bioavailability and high plasma protein binding (source: APExBIO product_spec). Anlotinib is metabolized primarily by CYP3A, and exhibits a favorable safety profile in preclinical models. APExBIO supplies this reagent for research use only, supporting advanced angiogenesis and cancer studies.

Biological Rationale

Angiogenesis, the formation of new blood vessels from existing vasculature, is essential for tumor growth and metastasis (source: Gene 2018). Tumor cells secrete pro-angiogenic cytokines, notably VEGF, PDGF-BB, and FGF-2, to drive endothelial cell migration and vessel formation. Inhibiting these pathways is a validated strategy for halting cancer progression. Multi-target tyrosine kinase inhibitors (TKIs) that block key pro-angiogenic receptors simultaneously offer a systems-level approach to suppress neovascularization and tumor expansion. Anlotinib hydrochloride exemplifies this approach by targeting VEGFR2, PDGFRβ, and FGFR1, the principal mediators of angiogenic signaling in cancer (source: APExBIO product_spec).

Mechanism of Action of Anlotinib hydrochloride

Anlotinib hydrochloride is a small-molecule inhibitor that selectively binds the ATP-binding sites of multiple receptor tyrosine kinases. Its primary targets are VEGFR2, PDGFRβ, and FGFR1, crucial for endothelial cell activation and angiogenesis. In biochemical assays, anlotinib inhibits VEGFR2 (IC₅₀: 5.6 ± 1.2 nM), PDGFRβ (IC₅₀: 8.7 ± 3.4 nM), and FGFR1 (IC₅₀: 11.7 ± 4.1 nM) (source: Gene 2018). This blockade prevents ligand-induced receptor phosphorylation and inhibits downstream ERK signaling, a pathway essential for endothelial cell proliferation, migration, and tube formation. Mechanistically, anlotinib disrupts capillary-like network assembly in vitro and suppresses microvessel density in ex vivo and in vivo angiogenesis models.

Evidence & Benchmarks

• Anlotinib hydrochloride inhibits VEGF/PDGF-BB/FGF-2-induced migration of EA.hy 926 endothelial cells in a concentration-dependent manner (source: Gene 2018, Fig. 2).
• Capillary tube formation assays confirm nanomolar potency, with complete inhibition observed at concentrations ≥ 10 nM (source: Gene 2018, Table 1).
• Anlotinib's inhibitory activity against VEGFR2 (IC₅₀: 5.6 nM), PDGFRβ (8.7 nM), and FGFR1 (11.7 nM) surpasses that of sunitinib, sorafenib, and nintedanib in head-to-head in vitro assays (source: Gene 2018, Fig. 1B).
• No significant cytotoxicity is observed at concentrations up to 1 μM in endothelial cell models, supporting use in functional assays (source: APExBIO product_spec).
• Pharmacokinetic studies in rats and dogs reveal oral bioavailability of 28%–58% (rats) and 41%–77% (dogs), with high plasma protein binding (93%–97%) and a terminal half-life of 5.1 h (rats) and 22.8 h (dogs) (source: APExBIO product_spec).
• Metabolism is primarily via CYP3A-mediated hydroxylation and dealkylation (source: APExBIO product_spec).
• Preclinical safety studies indicate a high median lethal dose (LD₅₀: 1735.9 mg/kg, 14-day oral, rat), with mild systemic toxicity and no significant organ, reproductive, or genetic toxicity (source: APExBIO product_spec).
• In vitro, anlotinib exhibits low risk for CYP-mediated drug-drug interactions despite weak inhibition of CYP3A4 and CYP2C9 (source: APExBIO product_spec).

For a detailed comparison of protocol setups, see this advanced guide to Anlotinib in angiogenesis assays—this dossier highlights fresh quantitative data and head-to-head benchmarks not covered previously.

For systems-level pathway analysis, this resource explores broader network effects, while the present article focuses on direct receptor/ERK pathway inhibition.

For translational insight and workflow strategy, our referenced expert article provides clinical application context, whereas this dossier centers on preclinical and research-grade validation.

Applications, Limits & Misconceptions

Anlotinib hydrochloride is intended for research use only and is not approved for clinical therapy outside regulated clinical trials. It is ideal for in vitro and ex vivo studies of angiogenesis, cancer biology, and receptor tyrosine kinase signaling. The compound's high specificity and low cytotoxicity enable its use in endothelial migration assays, capillary tube formation, and ERK pathway studies at nanomolar concentrations. Its robust pharmacokinetic and safety profile supports its use in preclinical animal models intended to elucidate angiogenesis mechanisms or test anti-tumor hypotheses. The agent is not recommended for use in models requiring broad-spectrum cytotoxicity, nor in non-angiogenic disease models without prior validation.

Common Pitfalls or Misconceptions

• Not a pan-kinase inhibitor: Anlotinib is selective for VEGFR2, PDGFRβ, and FGFR1, and does not broadly inhibit all receptor tyrosine kinases (source: Gene 2018).
• Low cytotoxicity at working concentrations: It is designed for functional, not cytotoxic, assays (source: APExBIO product_spec).
• Species and model limitations: Pharmacokinetic and safety data are derived from rodent and dog studies; human applicability requires further validation (source: APExBIO product_spec).
• Not a clinical therapeutic: Supplied by APExBIO strictly for non-human, non-clinical research applications (source: APExBIO product_spec).
• Workflow integration required: Protocols must be optimized for concentration, assay format, and exposure time to avoid off-target effects (workflow_recommendation).

Workflow Integration & Parameters

Protocol Parameters

• Assay: Endothelial cell migration inhibition | Value: 1–50 nM | Applicability: EA.hy 926, HUVEC, primary microvascular cells | Rationale: Potent inhibition of VEGF/PDGF-BB/FGF-2-induced migration at nanomolar range | Source: literature (Gene 2018)
• Assay: Capillary tube formation assay | Value: 10–100 nM | Applicability: Matrigel-based 2D and 3D assays | Rationale: Complete tube formation inhibition at ≥10 nM | Source: literature (Gene 2018)
• Assay: ERK signaling pathway inhibition | Value: 10–100 nM | Applicability: Western blot, phosphorylation readouts | Rationale: Inhibits ERK phosphorylation downstream of target RTKs | Source: literature (Gene 2018)
• Assay: Cytotoxicity (MTT, CellTiter-Glo) | Value: ≤1 μM | Applicability: Endothelial and tumor cell lines | Rationale: No significant cytotoxicity at ≤1 μM | Source: product_spec (APExBIO)
• Assay: Pharmacokinetic dosing (animal) | Value: 1–10 mg/kg oral | Applicability: Rat, dog | Rationale: Good oral bioavailability and low toxicity | Source: product_spec (APExBIO)
• Assay: Storage | Value: -20°C, desiccated | Applicability: All formats | Rationale: Maintains compound stability | Source: product_spec (APExBIO)

For comprehensive workflow optimizations, see protocol guides not covered in this mechanism-focused overview.

Conclusion & Outlook

Anlotinib hydrochloride, supplied by APExBIO, delivers robust, selective inhibition of angiogenic signaling at nanomolar concentrations and is validated in multiple functional and pharmacokinetic assays. Its use in research provides a reproducible platform for dissecting angiogenesis mechanisms and benchmarking anti-angiogenic agents. Future studies will extend these findings to more complex tumor microenvironment models, but translational use remains limited to non-human applications until further clinical data are available (source: Gene 2018). This article clarifies mechanistic strengths and experimental best practices, complementing broader systems-level and translational resources linked above.

For ordering and detailed specifications, consult the Anlotinib hydrochloride product page (SKU: C8688).